Immatics Presents First Cohort Data on the ACTolog® Personalized Multi-Target Cell Therapy Trial Demonstrating Safety and T-cell Persistence in Treated Cancer Patients
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, announced today a comprehensive data set having completed the first cohort of the ACTolog® Personalized Multi-Target T-cell Therapy Trial (Study code: IMA101-101, NCT02876510) at the AACR Special Conference on Immune Cell Therapies for Cancer.